Short Interest in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Drops By 67.5%

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totalling 478,400 shares, a drop of 67.5% from the December 15th total of 1,470,000 shares. Approximately 6.1% of the company’s stock are short sold. Based on an average trading volume of 1,770,000 shares, the days-to-cover ratio is currently 0.3 days.

Cumberland Pharmaceuticals Price Performance

Shares of NASDAQ CPIX remained flat at $2.33 during midday trading on Monday. 22,194 shares of the stock traded hands, compared to its average volume of 72,756. The firm’s 50 day moving average is $1.76 and its 200 day moving average is $1.49. Cumberland Pharmaceuticals has a 52-week low of $1.04 and a 52-week high of $3.05. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The stock has a market cap of $32.72 million, a P/E ratio of -3.03 and a beta of 0.13.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Cumberland Pharmaceuticals in a research note on Monday. They issued a “hold” rating on the stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.